Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Sandrine LemairePeter C Appelbaum

Abstract

Decreased susceptibility of Staphylococcus aureus to antistaphylococcal agents may be associated with inability to eradicate intracellular forms, which could explain therapeutic failures. This hypothesis was tested using clinical isolates obtained from a patient with persistent staphylococcal bacteraemia under therapy. Four isogenic isolates (three from tissue, one from blood) with increased MICs for vancomycin (1-4 mg/L) and for daptomycin (1-4 mg/L) were collected after an initial 16-day treatment with vancomycin-rifampicin-gentamicin, followed by 13-20 days of treatment with daptomycin-rifampicin-gentamicin. Isolates were tested for MICs and for: (i) vancomycin (BODIPY-FL-vancomycin) and daptomycin binding; (ii) cell wall turnover (loss of N-acetyl-d-[1-(14)C]glucosamine in 30 min after 1 h of labelling); and (iii) Triton X-100-induced autolysis. Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug b...Continue Reading

References

Jul 1, 1992·The Journal of Antimicrobial Chemotherapy·J F Desnottes, N Diallo
Dec 1, 1983·Journal of Bacteriology·H Y CheungE Freese
Jan 1, 1996·Drugs·P Vannuffel, C Cocito
Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Oct 21, 1999·International Journal of Antimicrobial Agents·P Collignon, J Turnidge
Aug 2, 2000·Trends in Microbiology·F D Lowy
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·M Maurin, D Raoult
May 3, 2003·The Journal of Clinical Investigation·Franklin D Lowy
May 23, 2003·Antimicrobial Agents and Chemotherapy·Susan Boyle-VavraRobert S Daum
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·Oleg KrutMartin Krönke
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pamela A Moise-BroderRobert C Moellering
Aug 19, 2005·The Journal of Infectious Diseases·Sophie ClementJean-Silvain Lacroix
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Tatiana BogdanovichPeter C Appelbaum
Jan 19, 2006·International Journal of Antimicrobial Agents·Pragya BhatejaAshok Rattan
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Longzhu CuiKeiichi Hiramatsu
Feb 1, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P C Appelbaum
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Maritza Barcia-MacayFrançoise Van Bambeke
Mar 10, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P C Appelbaum
Sep 12, 2006·International Journal of Antimicrobial Agents·Glenn W KaatzSusan M Seo
Apr 5, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fred C Tenover, Robert C Moellering
Sep 25, 2007·International Journal of Antimicrobial Agents·Peter C Appelbaum
Jan 9, 2008·International Journal of Antimicrobial Agents·Christof von Eiff
Feb 12, 2008·Trends in Pharmacological Sciences·Françoise Van BambekePaul M Tulkens

❮ Previous
Next ❯

Citations

May 13, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sandrine LemairePaul M Tulkens
Mar 28, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George G ZhanelJames A Karlowsky
May 4, 2011·Antimicrobial Agents and Chemotherapy·Lala M DunbarUNKNOWN SIMPLIFI Study Team
Dec 3, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G LuoA S Ibrahim
Jun 26, 2015·FEMS Microbiology Reviews·Marleen van OostenGooitzen M van Dam
Jan 15, 2018·Clinical Pharmacokinetics·Valentin Al Jalali, Markus Zeitlinger
Dec 25, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Lamis R KaraouiElias B Chahine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.